

September 8, 2023

Company Description

Emmaus Life Sciences, Inc. (“Emmaus” or “the Company”) is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies, primarily for rare and orphan diseases, with an initial focus on Sickle Cell Disease (SCD). Emmaus’ lead commercial product is Endari® (L-glutamine oral powder), an oral treatment indicated to reduce acute complications of SCD in adult and pediatric patients five years or older. Endari® is approved for marketing in the United States, Israel, Bahrain, Kuwait, Qatar, and the United Arab Emirates, and is available on a named patient or early access basis in France, The Netherlands, and the Kingdom of Saudi Arabia. As well, in July 2023, the Company announced that it had received marketing authorization from the Oman Ministry of Health for the commercial distribution. Emmaus is further aggressively seeking marketing approval in geographic regions that account for a significant share of the world’s SCD cases. Endari®’s growth continues to be driven by the effective use of its in-house sales force and its recently launched direct-to-consumer programs, including an innovative full-service telehealth solution that provides online access to Endari®. Emmaus is also involved in assessing L-glutamine to treat diverticulosis, currently in a pilot trial, as well as pre-clinical programs for oncology and regenerative medicine with other compounds. The Company believes its Endari® commercial activities and pipeline of new products provide a sustainable business model, which could result in multiple future revenue sources.

Key Points

- On August 14, 2023, Emmaus reported results of operations for the three and six month period ended June 30, 2023. The Company reported net revenues for the three months and six months ended June 30, 2023 of \$10.8 million and \$17.5 million, respectively, versus \$4.3 million and \$7.5 million, respectively, for same periods in 2022. The increase in net revenues was due to higher sales in the Middle East North Africa region and continuing recovery in U.S. sales versus 2022, resulting in over \$3.3 million in quarterly income from operations.
- Emmaus realized a net loss for the quarter of \$1.5 million, or \$0.03 per share based on approximately 52.9 million weighted average basic and diluted common shares. This compares to a net loss of \$8.9 million, or \$0.18 per share based on approximately 49.3 million weighted average basic and diluted common shares for the second quarter of 2022.
- On August 18, 2023, Emmaus reported that, the Board of Directors, including Yutaka Niihara, M.D., Ph.D, determined that Dr. Niihara would no longer serve as CEO of Emmaus, or as Chairman of the Board, in order to allow Dr. Niihara to pursue business opportunities in Ube, Japan and in India previously initiated by Emmaus. Emmaus also reported on August 21, 2023, that Willis Lee, who has long served as the Chief Operating Officer and a director of the Company, and George Sekulich, the Company’s Chief Commercial Officer, were appointed as interim Co-Presidents of Emmaus, to serve pending the Company’s search for a CEO.
- The global SCD treatment market was estimated at \$3.4 billion in 2020, and is expected to reach \$8.5 billion by 2026, behind an increasing prevalence of SCD and new innovative treatments. There are approximately 100,000 people living with SCD in the U.S. and millions more globally.
- Through its distribution agreements, the Company has accumulated a network of over 600 specialty and health system pharmacies distributing Endari®, with prescriptions having been filled in 46 states, Puerto Rico, and Washington D.C.
- As of June 30, 2023, the Company had cash and cash equivalents of \$1.4 million versus \$2.0 million on December 31, 2022.



Emmaus Life Sciences, Inc.
 21250 Hawthorne Blvd.
 Suite 800
 Torrance, CA 90503
 Phone: (310) 214-0065
<https://www.emmausmedical.com/>

EMMA (OTCQX) One-Year Chart



Ticker (Exchange)	EMMA (OTCQX)
Recent Price (09/08/2023)	\$0.15
52-week Range	\$0.07 – 0.59
Shares Outstanding	52.9 million
Market Capitalization	\$8.2 million
Avg. 10-day Volume	143,600
EPS (Qtr. ended 06/30/2023)	(\$0.03)
Employees	55

SECOND QUARTER 2023 FINANCIAL RESULTS

On August 14, 2023, Emmaus reported results of operations for the three and six month period ended June 30, 2023.

The Company reported net revenues for the three months and six months ended June 30, 2023 of \$10.8 million and \$17.5 million, respectively, versus \$4.3 million and \$7.5 million, respectively, for same periods in 2022. This increase was primarily attributable to a \$4.1 million increase in net revenues from sales in the Middle East North Africa (MENA) region in Q2 2023 and represented the sixth consecutive quarter of revenue growth for the Company. Net revenues in Q2 and the three months and six months ended June 30, 2023 also were positively affected by increased U.S. sales versus the same periods in 2022.

Total operating expenses for the three months ended June 30, 2023 were \$6.9 million versus \$5.3 million for the same periods in 2022. Of the increased operating expenses in Q2 2023, \$0.6 million was attributable to an increase in payroll expenses related to sales personnel and a \$1.0 million increase in general and administrative expenses. Total operating expenses for the six months ended June 30, 2023 were \$14.4 million versus \$10.6 million for the same period in 2022. The increase was due to a \$1.2 million increase in share-based compensation, a \$0.8 million increase in payroll expenses, and a \$0.6 million increase in consulting fees.

Income from operations for the three months ended June 30, 2023 was \$3.3 million versus a loss from operations of \$1.4 million in the same periods in 2022. Income from operations for the six months ended June 30, 2023 increased to \$2.2 million versus a loss from operations of \$4.5 million for the same period last year. The increased income from operation resulted from higher new revenues in 2023 versus 2022. Income from operations in Q2 2023 additionally grew by \$4.5 million, or 385%, from \$1.2 million loss from operations in Q1 2023 as a result of the increase in net revenues in Q2 2023.

Other expenses decreased to \$4.8 million for the three months ended June 30, 2023 versus \$7.3 million in the same period in 2022. Other expenses for the six months ended June 30, 2023 increase to \$7.2 million from \$5.8 million in the same period in 2022. Other expenses in Q2 2023 included a decrease of \$2.6 million in change in fair value of embedded conversion option of convertible promissory notes, partially offset by a \$0.5 million increase in interest expense versus Q2 2022.

Emmaus realized a net loss for the quarter of \$1.5 million, or \$0.03 per share based on approximately 52.9 million weighted average basic and diluted common shares. This compares to a net loss of \$8.9 million, or \$0.18 per share based on approximately 49.3 million weighted average basic and diluted common shares for the second quarter of 2022. The decrease in net loss was primarily attributable to the increase in income from operations and decrease in other expenses.

For the six months ended June 30, 2023, the Company reported a net loss of \$5.0 million, or \$0.10 per share, based on approximately 51.8 million weighted average basic and diluted common shares. This compares to a net loss of \$10.4 million, or \$0.21 per share, based on approximately 49.3 million weighted average basic and diluted common shares for the six months ended June 30, 2022. The decrease was due to the increase in net revenues, partially offset by the increase in operating expenses.

As of June 30, 2023, Emmaus had cash and cash equivalents of \$1.4 million versus \$2.0 million on December 31, 2022.

RECENT COMPANY DEVELOPMENTS

- **August 23, 2023**—Emmaus reported that on August 18, 2023, the Board of Directors, including Yutaka Niihara, M.D., Ph.D, determined that Dr. Niihara would no longer serve as CEO of Emmaus, or as Chairman of the Board, in order to allow Dr. Niihara to pursue business opportunities in Ube, Japan and in India previously initiated by Emmaus. Dr. Niihara was the principal inventor of Endari® (L-glutamine oral powder), which is approved in the U.S. and most of the Gulf Cooperation Council countries for the treatment of sickle cell disease, and long-time the Chairman of the Board and CEO of Emmaus. No rights of the Company have been granted to Dr. Niihara in these regards and he remains a director of the Company. Emmaus also reported that on August 21, 2023, Willis Lee, who has long served as the Chief Operating Officer and a director of the Company, and George Sekulich, the Company’s Chief Commercial Officer, were appointed as interim Co-Presidents of Emmaus, to serve pending the Company’s search for a CEO.
- **July 13, 2023**—Announced that it has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari® (L-glutamine oral powder) in the country to treat sickle cell disease in patients five years of age and older. There are around 3,000 patients with sickle cell disorders in Oman. The birth prevalence of infants with hemoglobin disorders was 3.5-4.7 per 1,000. Around 6% of Omanis are carriers of the gene for sickle cell anaemia. This marketing approval is an important step forward for Emmaus in the GCC region, where the Company has been working closely with the local authorities, physicians, and patient groups to ensure access to this treatment for sickle cell disease, with the Company seeking to expand Endari’s availability to other countries in the region.
- **May 31, 2023**—Announced that it has received a Medicine Registration Certificate (DRN-10164/23) from the Bahrain National Health Regulatory Authority (NHRA) granting marketing authorization for the commercial distribution and sale of Endari® in the Kingdom of Bahrain. Endari® is approved in the U.S., the United Arab Emirates, Israel, Kuwait, the State of Qatar, and Bahrain to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
- **May 15, 2023**—Reported on its financial condition and results of operations as of and for the three months ended March 31, 2023. The Company reported a fifth straight increase in quarterly net revenues and increased net revenues of 109% year-over-year on the strength of increased sales in the U.S. and the Middle East North Africa region. As a result, Emmaus was able to substantially reduce loss from operations and realized income from operations excluding share-based compensation.
- **April 3, 2023**—Announced preliminary results for the three months ended March 31, 2023. In the three months ended March 31, 2023, Emmaus shipped 8,248 boxes of Endari® to its U.S. and Middle East distributors, specialty pharmacies and other customers compared to 6,930 boxes in the three months ended December 31, 2022, a 19% increase. .
- **March 31, 2023**—Reported its results of operations for the year ended December 31, 2022 and an update on recent activities. Despite significant COVID-related interruptions that affected the Company’s net revenues in early 2022, there were steady and significant increases quarter over quarter throughout the rest of the year. Furthermore, the Company was able to get marketing authorization approvals for Endari in Qatar and Kuwait in Q4 2022 following approval in the U.A.E earlier in 2022.
- **December 20, 2022**—Announced that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the company, was hosted in Mumbai, India on December 16, 2022 by Bhagat Singh Koshiyari, the Governor of the State of Maharashtra, the industrial, financial and commercial center of India. In remarks on social media, <https://t.co/vTrKwVT4if>, the Governor cited the more than 20 million people suffering from SCD in his country and spoke of the discovery of Endari® that can help patients with SCD.

Company Background

Emmaus Life Sciences, Inc. (“Emmaus” or “the Company”) is a commercial-stage biopharmaceutical company that seeks to improve the lives of people through the discovery, development, and commercialization of innovative treatments and therapies, primarily for rare and orphan diseases, with an initial focus on Sickle Cell Disease (SCD). Emmaus’s lead commercial product, Endari® is an oral pharmaceutical-grade L-glutamine treatment indicated to reduce acute complications of SCD in adult and pediatric patients five years of age and older. Approved by the U.S. Food and Drug Administration (FDA) in 2017, Endari® has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission. Emmaus’ glutamine-based technology platform has also shown promise as an effective treatment for additional conditions beyond SCD, with the Company initially focused on using L-glutamine to treat diverticulosis, which is currently in a pilot trial. Emmaus’ product pipeline also includes pre-clinical programs, involving anti-cancer treatments as well as regenerative medicine technologies for the treatment of bone related conditions and corneal disease, among others.

Sickle Cell Disease (SCD)

Sickle Cell Disease (SCD) is a term that defines a group of rare hereditary blood disorders characterized by the production of an altered form of hemoglobin, the protein in red blood cells (RBCs) that carries oxygen to the tissues. Normal RBCs are smooth, disk-shaped, and flexible. SCD causes hemoglobin to become fibrous, resulting in RBCs that are sickle-shaped, rigid, and adhesive. These cells stick together and cannot easily move through the blood vessels, blocking small blood vessels and interfering with the delivery of oxygen to the body.

Patients with SCD suffer from debilitating episodes of sickle cell crises, a broad term covering a range of disorders that are considered to be the most devastating complication of SCD, which occur when the sickle-shaped RBCs block blood vessels. Sickle cell crises cause excruciating musculoskeletal and visceral pain, increased risk of heart attacks and strokes, and frequent infections. These complications tend to progress at adolescence and worsen during early adulthood and often lead to early mortality, with life expectancy of people with SCD approximately 20 to 25 years shorter than for the non-SCD population.

SCD Market and Incidence

The global SCD treatment market was estimated at \$3.4 billion in 2020, and is expected to reach \$8.5 billion by 2026, being driven by an increasing prevalence of SCD, rising awareness of the disease, increased spending in healthcare infrastructure in developing countries, and innovative treatments (Source: Expert Market Research’s *Global Sickle Cell Disease Treatment Market (2018-2028)*, 2022). The condition affects more than 100,000 people in the U.S. and an estimated 40 million to 50 million people worldwide, predominately in individuals with African, Middle Eastern, and Indian ancestry (Source: U.S. National Institutes of Health’s National Heart, Lung, and Blood Institute).

Current Therapeutic Options

The pharmacologic treatments currently available for SCD mainly focus on avoiding pain episodes, relieving symptoms, and preventing complications, while aiming to reduce the frequency of pain crises and the need for blood transfusions. Currently, only four therapeutic drugs have been approved by the FDA for the treatment of SCD: (1) hydroxyurea; (2) L-glutamine; (3) crizanlizumab; and (4) voxelotor. However, concerns about the safety and/or efficacy of some of these options are on-going. For example, hydroxyurea, approved by the FDA in 1998, contains a boxed warning (known as a black-label warning) highlighting the risk of severely low blood cell counts and cancer, the most stringent warning imposed by the FDA. And although voxelotor was shown to reduce hemolysis and anemia in patients with SCD in clinical trials, it did not demonstrate a statistically significant improvement in preventing the occlusion of blood vessels. Voxelotor’s mechanism of action, increasing hemoglobin’s oxygen affinity, presents some concerns of potential negative effects, as the bound oxygen might not be off loaded when needed, resulting in a potential risk for reduced oxygen delivery in tissues with high oxygen requirements, such as the brain and the heart.

ENDARI® (L-glutamine oral powder)

Endari® is a prescription oral treatment approved by the FDA to reduce the acute complications of SCD in adult and pediatric patients five years of age and older. Endari® was approved in July 2017 and, at the time, was the first ever FDA-approved treatment for pediatric patients with SCD (5+ years old) and the first new treatment for SCD in 20 years.

Phase 3 Clinical Trial

The FDA's approval of Endari® was based on the results of a 48-week placebo-controlled, multi-center Phase 3 clinical trial designed to evaluate the efficacy and safety of Endari® in 230 patients with SCD (5 to 58 years of age), with results published in *The New England Journal of Medicine* (Source: *New England Journal of Medicine*, Vol. 379:226-235, 2018).

Results of the trial demonstrated that the use of Endari® led to a reduction in the number of sickle cell crises by 25%, including a 63% reduction of acute chest syndrome occurrences, a potentially life-threatening obstruction of blood supply to the lungs characterized by fever, chest pain, cough, and lung infiltrates. Thirteen of 152 patients (8.6%) in the treated group had at least one episode of acute chest syndrome compared to 18 of 78 (23.1%) in the placebo group. Treatment with Endari® also resulted in a 56% delay in median time to first sickle cell crises (84 days vs. 54 days in the placebo group), as well as a significant reduction in median time to second sickle cell crises (212 days vs. 133 days in the placebo group).

Endari®'s use also resulted in fewer hospitalizations and fewer cumulative days in the hospital. Researchers found that Endari®'s positive effect on sickle cell crises resulted in a decrease of hospitalizations by 33% and a 41% decrease in cumulative hospital days (a median cumulative number of days in the hospital of 6.5 days vs. 11 days in the placebo group). These results were in line with a post-approval follow-up study assessing the use of Endari® in real world use. Compared to baseline, the use of Endari® resulted in significantly fewer vascular occlusion crises (VOCs), fewer hospitalizations, fewer days in the hospital, and fewer blood transfusions (Source: *HemaSphere*, Vol. 6 (Suppl):24-25, 2022).

Endari®'s Commercialization

Endari®'s commercialization efforts rely on the following key marketing advantages compared to other therapeutic options:

- *Broad indication:* Approved for any complication of SCD.
- *Pediatric usage:* Approved for patients aged 5 and up.
- *Real-world data:* On the market for approximately five years.
- *Significantly lower cost than new competitors:* Annual list price of \$40,500 in comparison to list prices of over \$100,000 for both Adakveo® (crizanlizumab) and Oxbryta™ (voxelotor).
- *Positive safety profile:* No warnings, precautions, or drug interaction notices on label.
- *No labs required:* No requirement of blood testing before or during taking the medication.

Emmaus is expanding the reach of Endari® through the effective use of its in-house sales force, which targets pediatric and adult SCD hematologists, physicians, and treatment centers. Approximately 86% of SCD patients in the U.S. reside in major metropolitan areas in 18 states. This allows Emmaus to have a more targeted sales approach, as a highly concentrated market allows for a more effective and smaller sales force.

To support its sales and distribution efforts, Emmaus has agreements in place with leading distributors, as well as physician groups, purchasing organizations, and pharmacy benefits managers. The Company has agreements with three of the largest specialty distributors of prescription drugs in the U.S.: AmerisourceBergen Corporation, McKesson Corporation, and Cardinal Health Inc. The Company also has a network of over 600 specialty and health system pharmacies distributing Endari[®], with prescriptions having been filled in 46 states, Puerto Rico, and Washington D.C. In addition, Endari[®] is well covered by various insurance programs, including Managed Medicare, the Children's Health Insurance Program (CHIP), commercial insurance, Medicare, and Medicaid.

Direct-to-Consumer Initiatives

The Company's U.S. marketing efforts include direct-to-consumer programs intended to reach individuals nationwide who lack information regarding available SCD treatment options, such as Endari[®]. An example of these initiatives is the collaboration between Emmaus and *The Steve Harvey Morning Show's* cast member Kier (Junior) Spates to share Mr. Spates' personal experience with the use of Endari[®] to treat his SCD during the show (link to interview <https://bit.ly/3HhQtjS>). *The Steve Harvey Morning Show* airs weekday mornings on more than 100 radio stations. The program is heard by nearly seven million weekly listeners and is the number one syndicated morning radio show in the U.S.

In addition, in April 2022, Emmaus launched an innovative full-service telehealth solution that provides online access to Endari[®]. The Company believes that of the approximately 100,000 sickle cell patients in the U.S., up to 75,000 can be accessed through telehealth, substantially more than the 25,000 accessible through traditional channels. Endari[®]'s telehealth program allows prospective patients to access a physician and perform an online appointment by phone or any device with internet access. The program allows for same day physician authorization and prescription, with medication sent to the patient's home within three business days.

The Company believes that Endari[®]'s safety profile and competitive advantage could result in the medication becoming the first choice SCD therapeutic candidate for patients using telemedicine services. In particular, the fact that Endari[®] does not require preliminary bloodwork to be prescribed or follow-up testing once it is administered, and the fact that Endari[®] has no FDA drug interaction limitations or warnings on its label, are key differentiators against competitive options that place Endari[®] in a better position to take advantage of the expansion of telemedicine in the U.S.

International Expansion

The Company believes that its international expansion is key to its future growth potential. Currently, Endari[®] is approved for use in the U.S. (2017), Israel (2020), United Arab Emirates (UAE) (March 2022), Qatar (November 2022), Kuwait (December 2022), Bahrain (2023), and Oman (2023). In addition, Emmaus is aggressively seeking additional marketing approvals for Endari[®] in geographic regions that account for a significant share of the world's SCD cases: the Middle East and North Africa (MENA), the Mediterranean (Europe), and South America.

Emmaus obtained marketing approval for Endari[®] in UAE, Qatar, Kuwait, Bahrain, and Oman; with submission for approval already filed in Saudi Arabia. Emmaus opened an office in Dubai in 2020 and entered into exclusive distribution agreements with strategic partners to register, commercialize, and distribute Endari[®] in the Gulf Cooperation Council countries and other countries throughout the MENA region. In November 2022, the Company announced that it had received the first major purchase order from its distributor in Saudi Arabia, where Endari[®] is available on an early access basis only.

The Company is also working to obtain marketing approval in EU and non-EU countries, with an initial focus on Early Access programs currently underway or planned in the UK, France, and Turkey. In addition, Emmaus is actively looking for distribution partners in Africa and Latin America (with a focus on Brazil and Colombia).

Historical Business Results

The Company launched Endari® in 2018, which resulted in approximately \$16.5 million in revenue for the fiscal year. Following its launch, acceptance of Endari® continued to increase, resulting in revenues of \$22.8 million in 2019. According to the Company, the COVID pandemic significantly affected its sales and marketing efforts, resulting in limited growth. However, despite this and the FDA approval of Adakveo® and Oxbryta™ in 2019, revenues in 2020 of \$23.2 million were in line with the previous year. Fiscal year 2021 resulted in a slight decrease in revenue (\$20.6 million) as a result of distributor overstocking of the medication as they accumulated inventory in line with pre-COVID sales expectations. This effect continued into the early part of 2022.

However, revenue numbers from the second half of 2022 show a steady growth once more. Weekly sales have continued to increase, reaching steady levels of \$500,000 to \$600,000 per week during the latter part of the year (equivalent to expected annualized sales of between \$26 million to \$31 million). The Company believes that this growth is due to a post-COVID shutdown recovery to normal business levels, coupled with the initial effects of its direct-to-consumer marketing initiatives that started in 2022. Emmaus believes that this domestic growth can continue behind the effect of its direct-to-consumer marketing programs, including expansion of its telehealth initiative.

This growth is in addition to the Company's international business expansion, where Endari® has received marketing approval in three Middle Eastern and North African (MENA) countries during 2022, with expectations for additional approvals in this region as well as in Europe and Asia.

Manufacturing Operations

Endari® uses prescription grade L-glutamine (PGLG), which differs from non-prescription grade L-glutamine widely available as a nutritional supplement in terms of purity and manufacturing oversight. Currently, Emmaus obtains all of its PGLG needs through a sourcing partnership with Ajinomoto Health and Nutrition North America, Inc. (Ajinomoto), a subsidiary of Ajinomoto North American Holdings, Inc.

Emmaus Clinical and Pre-Clinical Programs

L-glutamine has also shown promise in combating other conditions. The Company's pipeline includes two pre-clinical programs: (1) a regenerative medicine program based on **cell sheet technology**; and (2) an oncology program for solid cancers, blood-cancers, and lymphoma. The Company's technologies are also being investigated by third parties for the use of burn injuries (Phase 3) and pancreatic cancer (Phase 1), with study product provided by Emmaus. The Company believes that the combination of the commercially available Endari® in addition to its clinical and pre-clinical programs provide Emmaus with a sustainable business model and developing pipeline of new products, resulting in multiple potential future sources or revenue.

Headquarters, Corporate History, and Employees

Emmaus was incorporated in Delaware on March 20, 1987, under the name Age Research, Inc. Prior to January 16, 2007, it existed as a shell company with nominal assets. On January 16, 2007, the Company entered into an Agreement and Plan of Merger with CNS Response, Inc., and CNS Merger Corporation, its wholly owned subsidiary, pursuant to which CNS Merger Corporation merged with and into CNS Response, Inc. On November 2, 2015, the Company changed its corporate name to MYnd Analytics, Inc. On July 17, 2019, it completed a merger transaction with EMI Holding, Inc., formerly known as Emmaus Life Sciences, Inc. and changed its name to Emmaus Life Sciences, Inc. As of December 31, 2022, the Company had 55 employees, 53 of whom were full time. Emmaus' corporate offices are located in Torrance, California.

Risks and Disclosures

This Company Update has been prepared by Emmaus Life Sciences, Inc. (“Emmaus” or “the Company”) with the assistance of Crystal Research Associates, LLC (“CRA”) based upon information provided by the Company. CRA has not independently verified such information. Some of the information in this Update relates to future events or future business and financial performance. Such statements constitute forward-looking information within the meaning of the Private Securities Litigation Act of 1995. Such statements can only be predictions and the actual events or results may differ from those discussed due to the risks described in Emmaus’s statements on Forms 10-K, 10-Q, and 8-K as well as other forms filed from time to time.

The content of this report with respect to Emmaus has been compiled primarily from information available to the public released by the Company through news releases, Annual Reports, and U.S. Securities and Exchange Commission (SEC) filings. Emmaus is solely responsible for the accuracy of this information. Information as to other companies has been prepared from publicly available information and has not been independently verified by Emmaus or CRA. Certain summaries of activities and outcomes have been condensed to aid the reader in gaining a general understanding. CRA assumes no responsibility to update the information contained in this report. In addition, for year one of its agreement, CRA has been compensated by the Company in cash of forty-five thousand dollars and five hundred thousand warrants for its services in creating this report and for quarterly updates.

Investors should carefully consider the risks and information about Emmaus’s business. Investors should not interpret the order in which considerations are presented in their SEC filings as an indication of their relative importance. In addition, the risks and uncertainties overviewed in Emmaus’s SEC filings are not the only risks that the Company faces. Additional risks and uncertainties not presently known to Emmaus or that it currently believes to be immaterial may also adversely affect the Company’s business. If any of such risks and uncertainties develops into an actual event, Emmaus’s business, financial condition, and results of operations could be materially and adversely affected, and the trading price of the Company’s shares could decline.

This report is published solely for information purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state. Past performance does not guarantee future performance. For more complete information about the risks involved in an investment in the Company as well as for copies of this report, please contact Emmaus by calling (310) 214-0065.



About Our Firm: For almost two decades, Crystal Research Associates, LLC (www.crystalra.com) has successfully articulated the exceptional stories of small- and mid-cap companies to the Wall Street investor community. Our methods are well-established and diverse, from compiling and disseminating objective, factual information for both institutional and retail investor audiences to capitalizing on our expansive line of targeted distribution channels, which include industry-leading financial data and information providers. Our distribution efforts are accompanied using prominent social media channels and by strategic and targeted appearances on national news programs and print media.

Crystal Research Associates is led by Wall Street veterans, Jeffrey Kraws and Karen Goldfarb. Together, Kraws and Goldfarb have built a unique business model, capitalizing on decades of experience as an award-winning sell-side analyst team to produce institutional-quality industry and market research in a manner that is easily understood by investors and consumers. Our firm's approach has been proven successful over the years as our products are published and available on Bloomberg, Thomson Reuters/First Call, Capital IQ, FactSet, and scores of other popular forums.